Skip to content
inentertainment.co.uk
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Bambusa Therapeutics
Bambusa Therapeutics Presents Detailed BBT001 Atopic Dermatitis Proof-of-Concept Results at ISAD 2026
October 19, 2026
Bambusa Therapeutics Appoints Jonathan I. Lieber as Chief Financial Officer
October 7, 2026
Bambusa Therapeutics Initiates Subcutaneous Dosing of BBT001 in Atopic Dermatitis, Following Compelling Intravenous Proof-of-Concept Data
October 1, 2026
Bambusa Therapeutics Reports Potentially Transformative Preliminary Proof-of-Concept Results for BBT001 in Atopic Dermatitis, Reinforcing Its Best-in-Disease Potential
July 27, 2026
Bambusa Therapeutics Appoints Howard Liang, Ph.D. to its Board of Directors and Establishes Scientific Advisory Board
July 15, 2026